IPC Healthcare (IPCM) 10-K 23 Feb 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 16, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	IPC Healthcare, Inc.
Entity Central Index Key	1410471
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		17,282,657
Entity Public Float			$745,957,262

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$14,913	$25,010
Accounts receivable, net	122,092	103,585
Insurance receivable for malpractice claims - current portion	12,564	11,653
Prepaid expenses and other current assets	20,876	19,378
Total current assets	170,445	159,626
Property and equipment, net	8,798	6,343
Goodwill	408,988	357,387
Other intangible assets, net	4,957	5,857
Insurance receivable for malpractice claims - less current portion	21,574	20,599
Total assets	614,762	549,812
Current liabilities:
Accounts payable and accrued liabilities	8,388	5,486
Accrued compensation	40,907	35,639
Payable for practice acquisitions, current portion	35,411	32,430
Medical malpractice and self-insurance reserves, current portion	13,079	12,211
Deferred tax liabilities, current portion	584	969
Total current liabilities	98,369	86,735
Long-term debt	80,000	90,000
Medical malpractice and self-insurance reserves, less current portion	47,239	44,044
Payable for practice acquisitions, less current portion	9,500	8,289
Deferred tax liabilities, less current portion	11,737	5,762
Total liabilities	246,845	234,830
Stockholders’ equity:
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued	0	0
Common stock, $0.001 par value, 50,000,000 shares authorized, 17,242,209 and 17,015,580 shares issued and outstanding at December 31, 2014 and 2013, respectively	17	17
Additional paid-in capital	181,841	167,926
Retained earnings	186,059	147,039
Total stockholders’ equity	367,917	314,982
Total liabilities and stockholders’ equity	$614,762	$549,812

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	15,000,000	15,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	17,242,209	17,015,580
Common stock, shares outstanding	17,242,209	17,015,580

Consolidated_Statements_Income

Consolidated Statements Income (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Net revenue	$693,985	$609,517	$523,485
Operating expenses:
Cost of services—physician practice salaries, benefits and other	507,205	444,224	382,934
General and administrative	114,158	98,725	83,679
Net change in fair value of contingent consideration	2,252	-5,733	324
Depreciation and amortization	5,381	4,681	3,911
Total operating expenses	628,996	541,897	470,848
Income from operations	64,989	67,620	52,637
Investment income	5	13	14
Interest expense	-1,328	-540	-337
Income before income taxes	63,666	67,093	52,314
Income tax provision	24,646	25,697	19,728
Net income	$39,020	$41,396	$32,586
Net income per share:
Basic (usd per share)	$2.28	$2.46	$1.97
Diluted (usd per share)	$2.21	$2.39	$1.92

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
In Thousands, except Share data, unless otherwise specified
Beginning balance at Dec. 31, 2011	$212,652	$16	$139,579	$73,057
Beginning balance, shares at Dec. 31, 2011		16,474,988
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock	3,860	1	3,859
Issuance of common stock, shares		219,227
Stock-based compensation expense	6,344		6,344
Excess tax benefits from stock-based compensation	988		988
Tax deficiency and stock forfeiture related to stock-based compensation	-59		-59
Net income	32,586			32,586
Ending balance at Dec. 31, 2012	256,371	17	150,711	105,643
Ending balance, shares at Dec. 31, 2012		16,694,215
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock	7,429		7,429
Issuance of common stock, shares		321,365
Stock-based compensation expense	7,355		7,355
Excess tax benefits from stock-based compensation	2,609		2,609
Tax deficiency and stock forfeiture related to stock-based compensation	-178		-178
Net income	41,396			41,396
Ending balance at Dec. 31, 2013	314,982	17	167,926	147,039
Ending balance, shares at Dec. 31, 2013	17,015,580	17,015,580
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock	5,068		5,068
Issuance of common stock, shares		226,629
Stock-based compensation expense	8,282		8,282
Excess tax benefits from stock-based compensation	953		953
Tax deficiency and stock forfeiture related to stock-based compensation	-388		-388
Net income	39,020			39,020
Ending balance at Dec. 31, 2014	$367,917	$17	$181,841	$186,059
Ending balance, shares at Dec. 31, 2014	17,242,209	17,242,209

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating activities
Net income	$39,020	$41,396	$32,586
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	5,381	4,681	3,911
Stock-based compensation expense	8,282	7,355	6,344
Deferred income taxes	5,202	5,297	1,969
Changes in assets and liabilities:
Accounts receivable	-18,507	-23,973	-11,602
Prepaid expenses and other current assets	-1,498	-2,094	-4,145
Accounts payable and accrued expenses	2,439	1,229	295
Accrued compensation	5,268	6,455	6,975
Medical malpractice and self-insurance reserves, net	2,177	2,525	3,171
Accrued contingent consideration	-122	-6,075	324
Net cash provided by operating activities	47,642	36,796	39,828
Investing activities
Acquisitions of physician practices	-47,924	-104,127	-62,605
Purchase of property and equipment	-5,836	-3,911	-3,609
Net cash used in investing activities	-53,760	-108,038	-66,214
Financing activities
Proceeds from long-term debt	15,000	105,000	35,000
Repayments of long-term debt	-25,000	-35,000	-15,000
Net proceeds from issuance of common stock	5,068	7,429	3,860
Excess tax benefits from stock-based compensation	953	2,609	988
Net cash (used in) provided by financing activities	-3,979	80,038	24,848
Net (decrease) increase in cash and cash equivalents	-10,097	8,796	-1,538
Cash and cash equivalents, beginning of period	25,010	16,214	17,752
Cash and cash equivalents, end of period	14,913	25,010	16,214
Cash paid for:
Interest	1,336	513	251
Income taxes	19,081	17,227	17,805
Acquisitions of physician practices consisted of the following:
Acquired assets, net of assumed liabilities - goodwill, intangible and other	52,238	121,883	67,595
Increase in payable for practice acquisitions, excluding change in fair value of accrued contingent consideration	4,314	17,756	4,990
Net cash paid for acquisitions	$47,924	$104,127	$62,605

Operations_and_Significant_Acc

Operations and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Operations and Significant Accounting Policies	Operations and Significant Accounting Policies
	Business
	IPC Healthcare, Inc. and its subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time acute hospitalist and post-acute physician practices. Hospitalists focus on a patient’s care from the time of admission to discharge, working in close consultation with primary care physicians, other referring physicians and medical providers to coordinate the inpatient care delivery system and together with our post-acute clinicians manage the entire inpatient episode of care. Our affiliated clinicians practice in inpatient facilities, including acute care hospitals, long-term acute care facilities, specialty hospitals, psychiatric facilities and post-acute care facilities. The physicians are primarily full-time employees of our subsidiaries or consolidated Professional Medical Corporations, although part-time and temporary physicians are also employed or contracted on an as-needed basis. Also, unless otherwise expressly stated or the context otherwise requires, “our affiliated clinicians” refer to physicians, nurse practitioners and physician assistants employed or contracted by either our wholly-owned subsidiaries or our Professional Medical Corporations. References to “practices” or “practice groups” refer to our Professional Medical Corporations and the wholly-owned subsidiaries of IPC that provide medical services, unless otherwise expressly stated or the context otherwise requires.
	Principles of Consolidation
	Our consolidated financial statements include the accounts of IPC Healthcare, Inc. and its wholly owned subsidiaries and our affiliated professional medical corporations, also called “affiliated professional organizations”, which we manage under long-term management agreements. Some states have laws that prohibit business entities, such as IPC, from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians (collectively known as the corporate practice of medicine), or engaging in certain arrangements with physicians, such as fee-splitting. In states that have these restrictions, we operate by maintaining long-term management contracts with affiliated professional organizations, which are each owned and operated by physicians, and which employ or contract with additional clinicians to provide hospitalist and post-acute care services. Under the management agreements, we provide and perform all non-medical management and administrative services, including financial management, information systems, marketing, risk management and administrative support. The management agreements have an initial term of 20 years and are automatically renewable for successive 10-year periods unless terminated by either party for cause. The management agreements are not terminable by the Professional Medical Corporations, except in the case of gross negligence, fraud, or other illegal acts by us, or bankruptcy of IPC.
	Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have controls over the operations of these VIE’s, provide full financial and management support to them, and take all residual benefits and bear all residual losses from their operations. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation.
	Segment Reporting
	In accordance with U.S. generally accepted accounting principles (GAAP), the results of our operations are consolidated into a single reportable segment for purposes of presenting financial information.
	Revenue
	Net revenue consists of fees for medical services provided by our affiliated clinicians under fee-for-service, case rate and other professional fee arrangements with various payors including Medicare, Medicaid, managed care organizations, insurance companies and hospitals. For the years ended December 31, total patient volume consisted of the following percentage from Medicare and Medicaid programs:
			2014		2013		2012
	Medicare and Medicaid patients		54%		53%		52%
	Net revenue is reported in the period in which services are provided at amounts expected to be collected, which excludes contractual discounts and an estimate of uncollectible accounts. The process of estimating the ultimate amount of revenue to be collected is highly subjective and requires the application of our judgment based on many factors, including contractual reimbursement rates, payor mix, age of receivables, historical cash collection experience and other relevant information. We write off uncollectible accounts receivable from our billing system after reasonable collection efforts have been exhausted. The following amounts, which are excluded from our net revenues, represent an estimate of uncollectible patient copayments and deductible accounts related to patient services during the years ended December 31 (in thousands):
			2014		2013		2012
	Uncollectible accounts excluded from net revenue		$16,851		$15,274		$14,611
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. Significant estimates include the estimated net realizable value of accounts receivable, medical malpractice insurance receivable and payable for known claims, liabilities for claims incurred but not reported (IBNR) related to medical malpractice, fair value of contingent consideration related to business combinations and the analysis of goodwill for impairment.
	The process of estimating these assets and liabilities involves judgment decisions, which are subject to an inherent degree of uncertainty. Actual results could differ from those estimates.
	Fair Value of Financial Instruments
	Our consolidated balance sheets as of December 31, 2014 and 2013 included the following financial instruments: cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, payable for practice acquisitions and long-term debt. We consider the carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amount of our long-term debt borrowed from our line of credit in December 2014 approximated its fair value at December 31, 2014. Pursuant to GAAP, we determine the fair value of our long-term borrowing using inputs that can be corroborated by observable market data, which is defined as a Level 2 input under GAAP’s fair value hierarchy.
	Our payable for practice acquisitions consisted of accrued contingent consideration for practice acquisitions, which is carried at fair value determined using the income approach with unobservable inputs defined as Level 3 inputs under GAAP. See Note 3 for more information.
	Cash and Cash Equivalents
	Our cash and cash equivalents consist of bank deposits, money market accounts and short-term securities with maturities of three months or less.
	Accounts Receivable and Concentrations of Credit Risk
	Accounts receivable primarily consists of amounts due from third-party payors, including government sponsored Medicare and Medicaid programs, and insurance companies, and amounts due from hospitals, post-acute care facilities and patients. Accounts receivable are recorded and stated at the amount expected to be collected. The following amounts which are excluded from our accounts receivable, represent an estimate of uncollectible accounts at December 31 (in thousands):
			2014		2013
	Allowance for uncollectible accounts		$6,067		$6,510
	Except with respect to the Medicare and Medicaid programs, concentrations of credit risk, which consist primarily of accounts receivable, is limited due to the large number of payors comprising our diverse payor mix and patient base. Geographically, approximately 57%, 59% and 60% of our net revenue in 2014, 2013 and 2012, respectively, was generated by our operations in five states. For 2014 the five states are Arizona, Florida, Massachusetts, Michigan, and Texas. For 2013 and 2012, the five states are Arizona, Florida, Michigan, Missouri and Texas. As of December 31, accounts receivable from Medicare and Medicaid made up the following percentage of total net accounts receivable:
			2014		2013
	Percentage of receivables from Medicare and Medicaid		54%		43%
	Property and Equipment
	Property and equipment are stated on the basis of cost or fair value on the date of practice acquisition. Repairs and maintenance are charged to expense as incurred. Depreciation is provided using the straight-line method over the estimated useful lives of the assets. The depreciable life is generally three years for equipment and software, seven years for furniture, and the lesser of the useful life or lease period for leasehold improvements. At December 31, property and equipment consisted of the following (in thousands):
			2014				2013
	Furniture		$	3,057			$	2,803
	Computer equipment and software		24,154				19,685
	Office equipment		2,214				1,925
	Leasehold improvements		2,375				1,087
			31,800				25,500
	Less: Accumulated depreciation and amortization		(23,002		)		(19,157		)
			$	8,798			$	6,343
	For the years ended December 31, the following amounts were included in total depreciation and amortization expense (in thousands):
			2014		2013		2012
	Depreciation of property and equipment		$3,844		$3,377		$2,968
	Goodwill and Other Intangible Assets
	We record acquired assets and liabilities and any contingent consideration at their acquisition-date fair values, and expense all transaction related costs under the acquisition method of accounting. Goodwill represents the excess of cost over the fair value of the net assets acquired. Other intangible assets primarily represent the fair value of hospital service contract agreements and non-compete agreements acquired in connection with certain asset purchase agreements. Goodwill and other indefinite-lived intangible assets are not amortized. Separable identified intangible assets that have finite lives are amortized over their useful lives.
	In addition to the initial consideration paid at the close of each business combination, the asset purchase agreements for certain completed practice acquisitions provide for additional future consideration to be paid, which is generally based upon the achievement of certain operating results of the acquired practices or the occurrence of certain events as of certain measurement dates. Pursuant to GAAP, the estimated fair value of contingent consideration is accrued at the acquisition-date. Subsequent changes, if any, to the estimated fair value of contingent consideration are recognized as part of on-going operations.
	We test goodwill for impairment on an annual basis as of October 1 of each year, as well as when events or changes in business conditions indicate that the carrying amount of goodwill may not be recoverable, at the entity level since we have only one reporting unit pursuant to GAAP. The testing for impairment is completed using a two-step test. The first step compares the fair value of our Company with its carrying amount. The fair value of our Company is derived using the market-multiple valuation approach, which is based on our peer group’s market capitalization computed using publicly available market quotes. The fair value from the market-multiple approach is used to derive the fair value of our Company. If the fair value of our Company is less than its carrying amount, a second step is performed to determine the amount of any impairment loss. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. During 2014, 2013 and 2012, no impairment indicators were present and no impairment was recognized.
		2014		2013		2012
	Goodwill impairment	—		—		—
	The changes in the carrying amount of goodwill for the years ended December 31, 2014 and 2013 are as follows (in thousands):
			2014				2013
	Goodwill—beginning balance at January 1		$	357,387			$	240,009
	Goodwill acquired during year		53,462				119,437
	Goodwill adjustment for prior year transactions		(1,861		)		(2,059		)
	Goodwill—ending balance at December 31		$	408,988			$	357,387
	At December 31, other intangible assets consist of the following (in thousands):
			2014				2013
	Non-compete agreements		$	2,338			$	2,126
	Hospital and post-acute care facility contracts		10,513				10,088
	Trade name		70				70
			12,921				12,284
	Less: Accumulated amortization		(7,964		)		(6,427		)
			$	4,957			$	5,857
	For the years ended December 31, the following amortization of other intangible assets was included in total depreciation and amortization expenses (in thousands):
		2014		2013		2012
Amortization of other intangible assets		$1,537		$1,304		$943
Other intangible assets are being amortized over their estimated useful lives which range from three to six years and have a weighted average remaining useful life of 3.5 years at December 31, 2014. Future estimated aggregate amortization expenses are as follows (in thousands):
2015	$	1,160
2016	933
2017	688
2018	469
2019	469
Thereafter	1,238
	$	4,957
Medical Malpractice Liability Insurance
We maintain medical malpractice insurance coverage that indemnifies us and our employed health-care professionals on a claims-made basis. Our claims-made coverage covers those claims reported during the policy period, which ends December 31 of each year, on a first dollar coverage up to our policy limits on new claims reported during the policy period. In December 2014, we renewed our annual professional liability insurance policy for 2015 effective January 1, 2015 under the same terms as our 2014 policy. We expect to be able to continue to obtain coverage in future years; however, there can be no assurance that we will obtain substantially similar coverage as is provided under the 2015 policy at acceptable costs and on favorable terms upon expiration.
We record our medical malpractice reserves, on an undiscounted basis, for claims incurred and reported and claims incurred but not reported during the policy period, based on actuarial loss projections using historical loss patterns. For claims incurred and reported, an insurance receivable from our carrier has been recorded pursuant to GAAP.
Total accrued medical malpractice reserves and related insurance receivables at December 31 were as follows (in thousands):
		2014								2013
		Assets			Liabilities					Assets	Liabilities
		Insurance			Claims			IBNR	Total	Insurance	Claims	IBNR	Total
		Receivable			Reserve			Reserve	Liabilities	Receivable	Reserve	Reserve	Liabilities
Current Portion		$12,564			$12,564			515	13,079	$11,653	$11,653	558	12,211
Long-term Portion		21,574			21,574			25,665	47,239	20,599	20,599	23,445	44,044
Total		$34,138			$34,138			26,180	60,318	$32,252	$32,252	24,003	56,255
New Accounting Principles
In May 2014, the Financial Accounting Standard Board issued a GAAP update "Revenue from Contracts with Customers". This GAAP update requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. This GAAP update also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The GAAP update is effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2016. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year presentation.

Business_Acquisitions

Business Acquisitions	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Business Acquisitions	Business Acquisitions
	For practice acquisitions, we recognize all of the assets acquired, liabilities assumed and any contingent consideration at the acquisition-date fair value and expense all transaction related costs.
	During 2014, we completed the acquisition of 22 physician practices. In connection with these acquisitions, we recorded goodwill and other identifiable intangible assets consisting of physician, and hospital and post-acute care facility agreements. Goodwill represents the potential business synergy from the combined operations of our existing and acquired practices through an expanded national network of providers, improved managed care contracting, improved collections, identification of growth initiatives and cost savings based upon the significant infrastructure we have developed. Amounts recorded as goodwill and identifiable intangible assets are not amortizable for GAAP financial reporting purpose but are amortized for tax purposes over 15 years.
	In addition to the initial consideration paid at the close of each transaction, the asset purchase agreements for 21 of the 22 acquisitions completed during 2014 provide for contingent consideration to be paid, which is generally based upon the achievement of certain operating results of the acquired practices or the acquisition of certain other physician practices as of certain measurement dates. These additional payments are not contingent upon the future employment of the sellers. The estimated fair value of contingent consideration related to transactions is recognized at the acquisition-date. Subsequent changes, if any, to the estimated fair value of contingent consideration are recognized as part of on-going operations. In 2014, the net increase in the fair value of contingent consideration was $2.3 million. The contingent consideration for seven acquisitions completed during the three months ended December 31, 2014 was recorded on a provisional basis pending completion of the valuation studies as of the acquisition dates.
	We estimate the fair value of contingent consideration to be paid based on discounted projected earnings of the acquired practices as of certain measurement dates. The discount rate that we use consists of a risk-free U.S. Treasury bond yield plus a Company specific credit spread which we believe is acceptable by willing market participants.
	The following table summarizes the total amounts recorded during the years ended December 31, related to the acquisition of physician practices (in thousands):
		2014			2013
	Acquired assets, net of assumed liabilities—paid and accrued:
	Goodwill—current year transactions	$	53,462		$	119,437
	Other intangible assets	637			5,028
	Fixed assets	—			46
	Total acquired assets—current year	54,099			124,511
	Assumed accrued compensation liabilities	—			(569		)
	Goodwill—adjustment for prior year transactions	(1,861		)	(2,059		)
		52,238			121,883
	Cash paid for acquisitions:
	Current year transactions	(30,250		)	(91,322		)
	Contingent consideration	(17,674		)	(12,601		)
	Other—prior year transactions	—			(204		)
	Total cash paid for acquisitions	(47,924		)	(104,127		)
	Change in accrued contingent consideration	(122		)	(6,075		)
	Net change in payable for practice acquisitions	4,192			11,681
	Payable for practice acquisitions, beginning of period	40,719			29,038
	Payable for practice acquisitions, end of period	$	44,911		$	40,719
	During the fourth quarter of 2013, we acquired eight practices and in addition to the closing payments, we recorded accrued contingent consideration on a provisional basis pending completion of the valuation studies as of the acquisition date. The valuation studies were completed in 2014, resulting in a reduction of $1,861,000 of the accrued contingent consideration and the corresponding reduction to goodwill, which was recorded in 2014 as an adjustment for prior year transactions.

Fair_Value_Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement
	Some of our assets and liabilities are measured and recorded at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The established fair value hierarchy distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (Levels 1 and 2) and the reporting entity’s own assumptions about market participant assumptions (Level 3). This hierarchy is used to measure fair value as follows:
	•	Level 1 inputs utilize quoted prices in active markets for identical assets or liabilities.
	•	Level 2 inputs include quoted prices for similar assets and liabilities in active markets; quoted prices in markets that are not active; and other inputs that are observable or can be corroborated by observable market data for the asset or liability.
	•	Level 3 inputs are unobservable inputs for the asset or liability that are supported by little or no market activity.
	The following table presents our liabilities measured at fair value on a recurring basis as of December 31, 2014 and 2013 (in thousands):
	Accrued contingent consideration (included in payable for practice acquisitions)		Quoted Price In			Significant Other			Significant	Total Balance
			Active Markets for			Observable Inputs			Unobservable
			Identical Instruments			(Level 2)			Inputs
			(Level 1)						(Level 3)
	2014		$	—		$	—		$44,911	$44,911
	2013		$	—		$	—		$40,719	$40,719
	The following table presents a reconciliation for our liabilities measured at fair value on a recurring basis using significant unobservable inputs (level 3) for the years ended December 31, 2014 and 2013 (dollars in thousands):
	Accrued contingent consideration		2014			2013
	Beginning balance		$	40,719		$	28,834
	Addition through acquisition transactions		23,849			32,620
	Adjustment for prior year transactions		(1,861		)	(2,059		)
	Change in accrued contingent consideration		(122		)	(6,075		)
	Payments		(17,674		)	(12,601		)
	Ending balance		$	44,911		$	40,719
	The fair value of our accrued contingent consideration is determined using widely accepted valuation techniques, which include the income approach for estimating future consideration to be paid based on projected earnings of our acquired practices as of specified measurement dates. The income approach involves the use of a probability-weighted discounted cash flow model based on significant inputs not observable in the market. The significant inputs include a discount rate of 1.33% to 2.40%, and 10% to 100% probability of achieving the estimated projected earnings or the achievement of certain other objectives.
	Because our accrued contingent consideration is generally based on a certain multiple of earnings of the acquired practices during a specified measurement period, a relatively small change in such projected earnings may result in a material change to the fair value of such contingent consideration liability with a corresponding adjustment to income from operations. We reassess our projected earnings and the related fair value of our accrued contingent consideration for practice acquisitions on a quarterly basis.

Debt

Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt	Debt
	On October 23, 2013, we executed an amendment to our Credit Facility, which provides a revolving line of credit of $125.0 million and contains an “accordion” feature that allows an increase of up to $25.0 million to the Credit Facility with lender approval. The Credit Facility has a maturity date of August 4, 2016 and is available for working capital, practice acquisitions, capital expenditures and general business expenses. As of December 31, 2014, we had borrowings of $80.0 million and letters of credit of $0.3 million outstanding, and $44.7 million available under the Credit Facility.
	The revolving line of credit is limited by a formula based on a certain multiple times the trailing twelve months of earnings before interest, taxes, depreciation, amortization and certain non-cash items. Interest rate options for each borrowing under the Credit Facility, to be selected by us at the time of each borrowing, include either LIBOR plus 0.75% to 1.75%, or the lender’s prime rate plus 0% to 0.75%, both based on a leverage ratio. We pay an unused commitment fee equal to 0.25% per annum on the difference between the revolving line capacity and the average balance outstanding during the year. Outstanding amounts advanced to us under the revolving line of credit are repayable on or before the maturity date.
	The amended Credit Facility is guaranteed by our subsidiaries and affiliated Professional Medical Corporations and limited liability companies, and is secured by substantially all of our and our guarantors’ tangible and intangible assets. The Credit Facility includes various customary financial covenants and restrictions, as well as customary remedies for our lenders following an event of default. As of December 31, 2014, we were in compliance with such financial covenants and restrictions.
	Interest costs and unused commitment fees related to our debt and Credit Facility for the years ended December 31 are comprised of the following (in thousands):
		2014		2013		2012
	Interest expense	$	1,208	$	391	$	153
	Unused commitment fees	120		149		184
	Total interest expense	$	1,328	$	540	$	337

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	The following table represents the current and deferred income tax provision for federal and state income taxes attributable to operations (in thousands):
		2014				2013				2012
	Current:
	Federal	$	17,382			$	18,178			$	15,388
	State	2,031				2,222				2,312
	Total current(1)	19,413				20,400				17,700
	Deferred:
	Federal	3,856				4,322				1,997
	State	1,377				975				31
	Total deferred	5,233				5,297				2,028
	Total provision	$	24,646			$	25,697			$	19,728
	(1)    Current tax provision excludes tax benefit from stock compensation recorded to additional paid-in capital in the amount of:	$	(953	)		$	(2,609	)		$	(988	)
	A reconciliation of the provision for income taxes compared with U.S. statutory tax rates for the years ended December 31 is shown below:
		2014			2013			2012
	Statutory federal tax provision	35	%		35	%		35	%
	Increase (decrease) in taxes resulting from:
	State tax net of federal benefit	3.48	%		3.1	%		2.91	%
	Change in valuation allowance	(0.16	)%		0.05	%		(0.22	)%
	Permanent differences and other	0.39	%		0.15	%		0.01	%
	Recognition of tax benefits for uncertain positions	—	%		—	%		—	%
	Income tax provision	38.71	%		38.3	%		37.7	%
	In 2014, there was an increase in the overall effective tax rate primarily related to a discrete deferred tax asset valuation adjustment pertaining to the realization of certain state tax credits. In 2013, there was an increase in the overall effective tax rate primarily due to a change in state tax laws in November 2012.
	Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. At December 31, the significant components of our deferred tax assets and liabilities consisted of the following (in thousands):
		2014				2013
	Deferred tax assets:
	Net operating loss (NOL) carryforwards	$	581			$	575
	Allowance for uncollectible accounts	2,387				2,562
	Compensation accruals	1,779				1,564
	Accrued IBNR claims	10,302				9,445
	Stock-based compensation	8,102				6,611
	State taxes and credits	5,002				3,604
	Other	710				492
	Total deferred tax assets	28,863				24,853
	Less: Valuation allowance	(4,445		)		(2,746		)
	Deferred tax assets, net	24,418				22,107
	Deferred tax liabilities:
	Prepaid insurance	(5,596		)		(5,349		)
	Depreciation and amortization	(31,143		)		(23,489		)
	Total deferred tax liabilities	(36,739		)		(28,838		)
	Total net deferred tax liability	$	(12,321	)		$	(6,731	)
	We evaluate the recoverability of our deferred tax assets based on operations. The Company evaluated the positive and negative evidence related to their ability to utilize certain state credit carry forwards and concluded it is not more likely than not the credits will be fully utilized. California passed a tax law change in November, 2012 that reduced the Company’s annual credit utilization. Given this law change and considering all other available information, a partial valuation allowance of $4,199,000 was determined to be necessary. In addition, there is a valuation allowance related to consolidated Professional Medical Corporations that file separate tax returns for which the realization of the deferred tax asset is not more likely than not to be utilized. There is a net deferred tax liability at December 31, 2014 due to an increase in tax amortization of goodwill which has an indefinite reversal pattern.
	As of December 31, 2014 we have federal NOL carryforwards of $1,451,000 which begin to expire in 2019, and state NOL carryforwards of $1,663,000, which begin to expire in 2020. Federal NOLs of $390,000 incurred before 2000 are subject to an annual change of ownership limitation of approximately $195,000 per Internal Revenue Code Section 382 and applicable state statutes, which may limit our ability to utilize a portion of these losses.
	As of December 31, 2014 we have state credit carryforwards of $4,307,000 which will begin to expire on December 31, 2024. A partial valuation allowance of approximately $4,199,000 has been recorded against these credits due to the uncertainty of utilization.
	At December 31, 2014 we had no gross unrecognized tax benefits (UTB).
	Our accounting policy is to include interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2014 we did not have any accrued interest and penalties related to uncertain tax positions.
	The tax years 2009 to 2013 remain open to examination by the major taxing jurisdictions to which we are subject. The statute of limitations for tax years 1999 to 2008 has expired, except that the tax year 1999 is subject to adjustment of net operating losses by the Internal Revenue Service. We are subject to taxation in the United States and various state jurisdictions. The Company is currently subject to one state tax examination for the tax year of 2009. The outcome of such examination cannot be predicted with certainty; however, we believe that the ultimate resolution will not have a material effect on our financial position, results of operations, or cash flows.

Defined_Contribution_Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Defined Contribution Plan	Defined Contribution Plan
	Substantially all of our employees are eligible to participate in the IPC Healthcare, Inc. 401(k) Plan (the Plan). According to the Plan, we contribute half of the participant’s contributions when they are no greater than 7% of the participant’s annual compensation. The vesting period of our contribution is one year. After 60 days following an employee’s date of hire, all new-hires are automatically enrolled in the Plan. Employees that are automatically enrolled have 60 days to opt out of the Plan and to receive a refund of any contributions made in that period. We fund contributions as accrued. For the years ended December 31, expense recognized in connection with our contributions was (in thousands):
		2014	2013	2012
	Employer contribution to defined contribution plan	$9,941	$8,728	$7,484

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation
	At December 31, 2014, we had a stock-based employee compensation program, for which we had reserved a total of 4,943,170 common shares for issuance. Under our 2012 Equity Participation Plan (Equity Plan), which was approved by our stockholders on June 7, 2012, a total of 1,422,130 shares of our common stock were available for issuance and no new awards will be issued under any previous equity participation plans. As of December 31, 2014, there were 915,145 shares of our common stock available for future grants under our Equity Plan, which included the canceled and forfeited shares issued under previous equity participation plans.
	All option awards granted during 2014, 2013 and 2012 were issued with exercise prices equal to the closing price of our common stock on the NASDAQ Global Select Market on the dates of the grant. The options under the Equity Plan generally vest over a four-year period from date of grant, and options terminate on the 10th anniversary of the agreement date for all grants issued before January 1, 2013 and on the 7th anniversary of the agreement date for all grants issued after December 31, 2012. Restricted stock awards generally vest over a four-year period from date of the award. Performance stock awards generally vest over two to three years from date of the award based on the expected level of achievement of certain operational goals that will be obtained and adjusted as appropriate to reflect actual shares issued.
	Stock-based compensation expense is recognized over the period when the options, restricted stock awards, performance stock awards and our employee stock purchase plan shares vest, which is included in total general and administrative expenses. The following table summarizes the components of stock-based compensation expense recognized in our Consolidated Statement of Income for 2014, 2013 and 2012 (in thousands):
		2014				2013				2012
	Total stock-based compensation expense	$	8,282			$	7,355			$	6,344
	Tax benefit from stock-based compensation expense	(3,205		)		(2,817		)		(2,392		)
	Total stock-based compensation expense, net of tax	$	5,077			$	4,538			$	3,952
	As of December 31, 2014, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under our Equity Plan and the weighted-average period of years expected to recognize those costs are as follows (dollars in thousands).
		Total Unrecognized				Weighted-Average
		Compensation Cost				Remaining Contractual
						Term
						(Years)
	Stock option	$	1,687			5.22
	Restricted stock	$	6,603			1.16
	The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions:
		For Years Ended December 31,
		2014			2013			2012
	Risk-free interest rate	1.1	%		0.67	%		1.21	%
	Expected volatility	37.11	%		40.07	%		39.86	%
	Expected option life (in years)	4.44			4.4			6.16
	Expected dividend yield	—	%		—	%		—	%
	The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero coupon issues. The expected volatility is largely based on the volatility of our stock price. The expected option life of each award granted was calculated using the “simplified method” in accordance with GAAP.
	The grant date fair value of each restricted stock award or performance stock award is based on the closing stock price on the grant date of the award as reported by NASDAQ Global Select Market.
	The following table summarizes the stock option activity in our Equity Plan during the year ended December 31, 2014.
		Shares			Weighted-				Weighted-		Aggregate		Weighted-
					Average				Average		Intrinsic Value		Average Fair
					Exercise Price				Remaining				Value
									Contractual
									Term
									(Years)		(in 000’s)
	Options outstanding as of December 31, 2013	1,380,425			$	30.12							$	12.56
	Changes during period:
	Granted	44,885			53.74								17.2
	Exercised	(151,008	)		25.87								10.99
	Cancelled	(39,772	)		42.41								17.91
	Expired
	Options outstanding as of December 31, 2014	1,234,530			$	31.1			5.22		$	18,661	$	12.75
	Options exercisable as of December 31, 2014	1,113,763			$	29.92			5.07		$	18,041	$	12.4
	The total intrinsic value of stock options exercised during the year ended December 31, 2014 was $2,999,000.
	The following table summarizes the restricted stock award and performance stock award activities in our Equity Plan during the year ended December 31, 2014.
		Shares			Weighted-		Aggregate				Weighted-
					Average		Intrinsic Value				Average Fair
					Remaining						Value
					Contractual
					Term
					(Years)		(in 000’s)
	Restricted/performance stock awards outstanding as of December 31, 2013	212,413									$	40.29
	Changes during period:
	Granted	119,293									51.94
	Vested	(55,071	)								38.82
	Cancelled/Forfeited	(11,416	)								43.46
	Restricted/performance stock awards outstanding as of December 31, 2014	265,219			1.16		$	12,171			$	45.69

Employee_Stock_Purchase_Plan

Employee Stock Purchase Plan	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Stock Purchase Plan	Employee Stock Purchase Plan
	We have a nonqualified employee stock purchase plan (ESPP), which authorizes the issuance of up to an aggregate of 306,250 shares of our common stock to eligible employees who meet the service requirements. At the end of each annual offering period under the plan, an automatic purchase of our common stock is made on behalf of the plan’s participants. Eligible employees may purchase common stock through payroll deductions in amounts from $500 to $10,000 per year. Employees may reduce or suspend deductions during the year or withdraw from the plan during the year and receive a refund of their deductions. Stock purchases are made at a price equal to 85% of the fair market value (i.e., closing price of our common stock on the NASDAQ Global Select Market) of a share of our common stock on the first or last day of the offering period, whichever is lower.
	For the years ended December 31, the stock-based compensation expense relating to the ESPP was included in general and administrative expenses as follows (in thousands):
		2014	2013	2012
	Stock-based compensation expense related to ESPP	$290	$329	$309

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share
	Basic net income per share is calculated by dividing net income for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing net income for the period by the weighted average number of shares outstanding during the period plus the dilutive effect of our outstanding stock awards and shares issuable under our employee stock purchase plan using the treasury stock method.
	The calculations of basic and diluted net income per share for the years ended December 31 are as follows (dollar in thousands, except for per share data):
		2014			2013		2012
	Basic:
	Net income attributable to common stockholders	$	39,020		$	41,396	$	32,586
	Weighted average number of common shares outstanding	17,145,017			16,811,571		16,578,994
	Basic net income per share attributable to common stockholders	$	2.28		$	2.46	$	1.97
	Diluted:
	Net income attributable to common stockholders	$	39,020		$	41,396	$	32,586
	Weighted average number of common shares outstanding	17,145,017			16,811,571		16,578,994
	Weighted average number of dilutive common share equivalents from options to purchase common stock	474,033			503,188		389,151
	Common shares and common share equivalents	17,619,050			17,314,759		16,968,145
	Diluted net income per share	$	2.21		$	2.39	$	1.92
	Outstanding stock options, which have an exercise price above market or which are anti-dilutive under the treasury stock method, are excluded from our diluted computation. As of December 31, the excluded stock options were as follows:
		2014		2013	2012
	Stock options excluded from diluted shares computation	79,635		28,194	430,489

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Leases
	We lease certain buildings and equipment under operating leases. Certain building leases contain renewal options. Future minimum rental payments required under operating leases that have initial or remaining non-cancelable leases as of December 31, 2014, are as follows (in thousands):
	2015	$	4,879
	2016	4,648
	2017	4,145
	2018	3,722
	2019	1,426
	Thereafter	2,319
		$	21,139
	We do not have contingent rent and sub-lease agreements. Rent expense recorded for years ended December 31 was as follows (in thousands):
			2014	2013	2012
	Total rent expense		$4,402	$3,595	$3,330
	Regulatory Matters
	Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medicaid programs. We believe that we are in compliance with all applicable laws and regulations. However, we are in litigation with the Department of Justice (DOJ) as discussed under “Government Claim” section below.
	We operate in certain states regulated under corporate practice of medicine laws and we believe that we are in compliance with all such laws.
	Legal
	In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated clinicians. We may also become subject to other lawsuits, which could involve significant claims and/or significant defense costs.
	We believe, based upon our review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, or cash flows in a future period.
	Government Claim
	On June 7, 2010, we received a civil investigative demand (CID) issued by the Department of Justice (DOJ), U.S. Attorney’s Office for the Northern District of Illinois. The CID requested information concerning claims that we have submitted to Medicare and Medicaid. The CID covered the period from January 1, 2003, through June 4, 2010, and requested production of a range of documents relating to our Medicare and Medicaid participation, physician arrangements, operations, billings and compliance programs. We believe we have a strong compliance focus, and that we operate with appropriate billing policies, procedures, provider training, and compliance programs and controls. We produced responsive documents and were in contact with representatives of the DOJ who informed us that the inquiry related to a qui tam whistleblower action filed under court seal in the U.S. District Court for the Northern District of Illinois (Chicago). We also were informed that several state attorneys general were examining our Medicaid claims in coordination with the DOJ.
	Though we cooperated with the government’s investigation and would welcome a resolution to this matter, we are now in active litigation with the federal government regarding this matter and intend to contest the case vigorously. On December 6, 2013, the U.S. District Court partially lifted the seal on the civil False Claims Act case related to this investigation. The unsealed portions of the Court docket include the whistleblower’s Complaint, which contains allegations of improper billing to Medicare and Medicaid, a Notice of Election to Intervene filed by the federal government and a Notice of Election to Decline Intervention filed by the State of Illinois and 12 other states that participated in the investigation. On June 16, 2014, the federal government filed its Complaint in Intervention against IPC and several of its subsidiaries in the U.S. District Court. The Complaint in Intervention contains allegations of improper billing to Medicare, Medicaid and other federal programs from January 1, 2003 to the present, seeks to recover treble damages and civil penalties under the civil False Claims Act, and seeks to recover damages under the common law theories of payment by mistake and unjust enrichment. On August 13, 2014, IPC and the IPC subsidiary defendants filed a joint motion to dismiss the Complaint in Intervention or, in the alternative, to sever claims against the defendants. The federal government filed its response on September 18, 2014, to which the defendants replied on September 25, 2014. The court’s decision, which was filed on February 17, 2015, grants the motion to dismiss in part and denies it in part. The Court’s Opinion and Order dismisses the 29 IPC subsidiary and affiliate defendants without prejudice, but the Court denies the request to dismiss IPC, which remains the sole defendant in the lawsuit.
	It is not possible to predict when this matter may be resolved, the time or resources that we will need to devote to this litigation, or what impact, if any, the outcome of this matter might have on our consolidated financial position, results of operations, or cash flows.
	Derivative Lawsuit
	Although the underlying government lawsuit is still in an early stage and no liability has been found by a court, on October 20 and 24, 2014, shareholder derivative lawsuits were filed in the Court of Chancery of the State of Delaware against certain of our current and former directors and officers.  We are named as a nominal defendant in both suits.  The actions both assert alleged breaches of fiduciary duties related to our billing practices, and incorporate allegations from the False Claims Act case.  The lawsuits seek a variety of relief, including monetary damages and injunctive relief.  On December 4, 2014, the derivative lawsuits were consolidated into one lawsuit. The litigation is in an early stage and it is not possible to predict when this matter may be resolved, the time or resources that we will need to devote to this litigation, or what impact, if any, the outcome of this matter might have on our consolidated financial position, results of operations, or cash flows.
	Liability Insurance
	Although we currently maintain liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may not continue to be available to us in future years at acceptable costs, and on favorable terms. In addition to the known incidents occurring through December 31, 2014 that have resulted in the assertion of claims, we cannot be certain that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us in the future where the outcomes of such claims are unfavorable.
	We believe that the ultimate resolution of all pending claims, including liabilities in excess of our insurance coverage, will not have a material adverse effect on our financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have a material adverse effect on our business.

Quarterly_Results_of_Operation

Quarterly Results of Operations	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Results of Operations	Quarterly Results of Operations (unaudited)
	Following is a summary of our quarterly results of operations for the years ended December 31, 2014 and 2013 (dollars in thousands, except for per share data):
			Dec 31,			Sep 30,			Jun 30,			Mar 31,			Dec 31,			Sep 30,			Jun 30,			Mar 31,
			2014			2014			2014			2014			2013			2013			2013			2013
	Net revenue		$	179,234		$	169,757		$	172,268		$	172,726		$	161,600		$	149,073		$	145,753		$	153,091
	Income from operations		16,142			14,307			17,576			16,964			15,658			14,791			20,032			17,139
	Investment income		1			2			1			1			1			7			3			2
	Interest expense		(271		)	(361		)	(382		)	(314		)	(217		)	(109		)	(99		)	(115		)
	Income before income taxes		15,872			13,948			17,195			16,651			15,442			14,689			19,936			17,026
	Income tax provision		6,342			5,341			6,586			6,377			5,915			5,626			7,635			6,521
	Net income		$	9,530		$	8,607		$	10,609		$	10,274		$	9,527		$	9,063		$	12,301		$	10,505
	Per share data:
	Net income per share(1):
	Basic		$	0.55		$	0.5		$	0.62		$	0.6		$	0.56		$	0.54		$	0.73		$	0.63
	Diluted		$	0.54		$	0.49		$	0.61		$	0.58		$	0.54		$	0.52		$	0.71		$	0.61
	Weighted average shares:
	Basic		17,211,617			17,187,819			17,123,840			17,054,598			16,937,646			16,839,069			16,763,325			16,703,369
	Diluted		17,655,522			17,652,892			17,515,938			17,567,583			17,516,086			17,368,426			17,228,173			17,125,940
	-1	Earnings per share are computed independently for each of the quarters presented and therefore may not sum to the total for the year.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events (unaudited)
	Subsequent to December 31, 2014, we completed four practice acquisitions. On January 2, 2015, we changed our company's name from IPC The Hospitalist Company, Inc. to IPC Healthcare, Inc.

Schedule_II_Valuation_and_Qual

Schedule II: Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Schedule II: Valuation and Qualifying Accounts	SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS
		Years Ended December 31,
		2014			2013			2012
		(in thousands)
	Allowance for uncollectible accounts were as follows:
	Balance at beginning of year	$	6,510		$	4,837		$	4,831
	Amount charged against operating revenue	16,851			15,274			14,611
	Accounts receivable write-offs (net of recovery)	(17,294		)	(13,601		)	(14,605		)
	Balance at end of year	$	6,067		$	6,510		$	4,837

Operations_and_Significant_Acc1

Operations and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Business	Business
	IPC Healthcare, Inc. and its subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time acute hospitalist and post-acute physician practices. Hospitalists focus on a patient’s care from the time of admission to discharge, working in close consultation with primary care physicians, other referring physicians and medical providers to coordinate the inpatient care delivery system and together with our post-acute clinicians manage the entire inpatient episode of care. Our affiliated clinicians practice in inpatient facilities, including acute care hospitals, long-term acute care facilities, specialty hospitals, psychiatric facilities and post-acute care facilities. The physicians are primarily full-time employees of our subsidiaries or consolidated Professional Medical Corporations, although part-time and temporary physicians are also employed or contracted on an as-needed basis. Also, unless otherwise expressly stated or the context otherwise requires, “our affiliated clinicians” refer to physicians, nurse practitioners and physician assistants employed or contracted by either our wholly-owned subsidiaries or our Professional Medical Corporations. References to “practices” or “practice groups” refer to our Professional Medical Corporations and the wholly-owned subsidiaries of IPC that provide medical services, unless otherwise expressly stated or the context otherwise requires.
Principles of Consolidation	Principles of Consolidation
	Our consolidated financial statements include the accounts of IPC Healthcare, Inc. and its wholly owned subsidiaries and our affiliated professional medical corporations, also called “affiliated professional organizations”, which we manage under long-term management agreements. Some states have laws that prohibit business entities, such as IPC, from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians (collectively known as the corporate practice of medicine), or engaging in certain arrangements with physicians, such as fee-splitting. In states that have these restrictions, we operate by maintaining long-term management contracts with affiliated professional organizations, which are each owned and operated by physicians, and which employ or contract with additional clinicians to provide hospitalist and post-acute care services. Under the management agreements, we provide and perform all non-medical management and administrative services, including financial management, information systems, marketing, risk management and administrative support. The management agreements have an initial term of 20 years and are automatically renewable for successive 10-year periods unless terminated by either party for cause. The management agreements are not terminable by the Professional Medical Corporations, except in the case of gross negligence, fraud, or other illegal acts by us, or bankruptcy of IPC.
	Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have controls over the operations of these VIE’s, provide full financial and management support to them, and take all residual benefits and bear all residual losses from their operations. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation.
Segment Reporting	Segment Reporting
	In accordance with U.S. generally accepted accounting principles (GAAP), the results of our operations are consolidated into a single reportable segment for purposes of presenting financial information.
Revenue	Revenue
	Net revenue consists of fees for medical services provided by our affiliated clinicians under fee-for-service, case rate and other professional fee arrangements with various payors including Medicare, Medicaid, managed care organizations, insurance companies and hospitals.
	Net revenue is reported in the period in which services are provided at amounts expected to be collected, which excludes contractual discounts and an estimate of uncollectible accounts. The process of estimating the ultimate amount of revenue to be collected is highly subjective and requires the application of our judgment based on many factors, including contractual reimbursement rates, payor mix, age of receivables, historical cash collection experience and other relevant information. We write off uncollectible accounts receivable from our billing system after reasonable collection efforts have been exhausted.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. Significant estimates include the estimated net realizable value of accounts receivable, medical malpractice insurance receivable and payable for known claims, liabilities for claims incurred but not reported (IBNR) related to medical malpractice, fair value of contingent consideration related to business combinations and the analysis of goodwill for impairment.
	The process of estimating these assets and liabilities involves judgment decisions, which are subject to an inherent degree of uncertainty. Actual results could differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	Our consolidated balance sheets as of December 31, 2014 and 2013 included the following financial instruments: cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, payable for practice acquisitions and long-term debt. We consider the carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amount of our long-term debt borrowed from our line of credit in December 2014 approximated its fair value at December 31, 2014. Pursuant to GAAP, we determine the fair value of our long-term borrowing using inputs that can be corroborated by observable market data, which is defined as a Level 2 input under GAAP’s fair value hierarchy.
	Our payable for practice acquisitions consisted of accrued contingent consideration for practice acquisitions, which is carried at fair value determined using the income approach with unobservable inputs defined as Level 3 inputs under GAAP. See Note 3 for more information.
Cash and Cash Equivalents	Cash and Cash Equivalents
	Our cash and cash equivalents consist of bank deposits, money market accounts and short-term securities with maturities of three months or less.
Accounts Receivable	Accounts receivable primarily consists of amounts due from third-party payors, including government sponsored Medicare and Medicaid programs, and insurance companies, and amounts due from hospitals, post-acute care facilities and patients. Accounts receivable are recorded and stated at the amount expected to be collected.
Concentrations of Credit Risk	Except with respect to the Medicare and Medicaid programs, concentrations of credit risk, which consist primarily of accounts receivable, is limited due to the large number of payors comprising our diverse payor mix and patient base.
Property and Equipment	Property and Equipment
	Property and equipment are stated on the basis of cost or fair value on the date of practice acquisition. Repairs and maintenance are charged to expense as incurred. Depreciation is provided using the straight-line method over the estimated useful lives of the assets. The depreciable life is generally three years for equipment and software, seven years for furniture, and the lesser of the useful life or lease period for leasehold improvements.
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets
	We record acquired assets and liabilities and any contingent consideration at their acquisition-date fair values, and expense all transaction related costs under the acquisition method of accounting. Goodwill represents the excess of cost over the fair value of the net assets acquired. Other intangible assets primarily represent the fair value of hospital service contract agreements and non-compete agreements acquired in connection with certain asset purchase agreements. Goodwill and other indefinite-lived intangible assets are not amortized. Separable identified intangible assets that have finite lives are amortized over their useful lives.
	In addition to the initial consideration paid at the close of each business combination, the asset purchase agreements for certain completed practice acquisitions provide for additional future consideration to be paid, which is generally based upon the achievement of certain operating results of the acquired practices or the occurrence of certain events as of certain measurement dates. Pursuant to GAAP, the estimated fair value of contingent consideration is accrued at the acquisition-date. Subsequent changes, if any, to the estimated fair value of contingent consideration are recognized as part of on-going operations.
	We test goodwill for impairment on an annual basis as of October 1 of each year, as well as when events or changes in business conditions indicate that the carrying amount of goodwill may not be recoverable, at the entity level since we have only one reporting unit pursuant to GAAP. The testing for impairment is completed using a two-step test. The first step compares the fair value of our Company with its carrying amount. The fair value of our Company is derived using the market-multiple valuation approach, which is based on our peer group’s market capitalization computed using publicly available market quotes. The fair value from the market-multiple approach is used to derive the fair value of our Company. If the fair value of our Company is less than its carrying amount, a second step is performed to determine the amount of any impairment loss. We review our finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Medical Malpractice Liability Insurance	Medical Malpractice Liability Insurance
	We maintain medical malpractice insurance coverage that indemnifies us and our employed health-care professionals on a claims-made basis. Our claims-made coverage covers those claims reported during the policy period, which ends December 31 of each year, on a first dollar coverage up to our policy limits on new claims reported during the policy period. In December 2014, we renewed our annual professional liability insurance policy for 2015 effective January 1, 2015 under the same terms as our 2014 policy. We expect to be able to continue to obtain coverage in future years; however, there can be no assurance that we will obtain substantially similar coverage as is provided under the 2015 policy at acceptable costs and on favorable terms upon expiration.
	We record our medical malpractice reserves, on an undiscounted basis, for claims incurred and reported and claims incurred but not reported during the policy period, based on actuarial loss projections using historical loss patterns. For claims incurred and reported, an insurance receivable from our carrier has been recorded pursuant to GAAP.
New Accounting Principles	New Accounting Principles
	In May 2014, the Financial Accounting Standard Board issued a GAAP update "Revenue from Contracts with Customers". This GAAP update requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. This GAAP update also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The GAAP update is effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2016. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.
Reclassifications	Reclassifications
	Certain prior year amounts have been reclassified to conform to the current year presentation.

Operations_and_Significant_Acc2

Operations and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Medicare and Medicaid Percentage of Total Patient Volume	For the years ended December 31, total patient volume consisted of the following percentage from Medicare and Medicaid programs:
			2014		2013		2012
	Medicare and Medicaid patients		54%		53%		52%
Schedule of Amount Excluded from Revenues that Represents Uncollectible Patient Copayment and Deductible Amounts	The following amounts, which are excluded from our net revenues, represent an estimate of uncollectible patient copayments and deductible accounts related to patient services during the years ended December 31 (in thousands):
			2014		2013		2012
	Uncollectible accounts excluded from net revenue		$16,851		$15,274		$14,611
Schedule of Amount Excluded from Accounts Receivable	The following amounts which are excluded from our accounts receivable, represent an estimate of uncollectible accounts at December 31 (in thousands):
			2014		2013
	Allowance for uncollectible accounts		$6,067		$6,510
	As of December 31, accounts receivable from Medicare and Medicaid made up the following percentage of total net accounts receivable:
			2014		2013
	Percentage of receivables from Medicare and Medicaid		54%		43%
Schedule of Property and Equipment	At December 31, property and equipment consisted of the following (in thousands):
			2014				2013
	Furniture		$	3,057			$	2,803
	Computer equipment and software		24,154				19,685
	Office equipment		2,214				1,925
	Leasehold improvements		2,375				1,087
			31,800				25,500
	Less: Accumulated depreciation and amortization		(23,002		)		(19,157		)
			$	8,798			$	6,343
	For the years ended December 31, the following amounts were included in total depreciation and amortization expense (in thousands):
			2014		2013		2012
	Depreciation of property and equipment		$3,844		$3,377		$2,968
Schedule of Changes in Carrying Amount of Goodwill	During 2014, 2013 and 2012, no impairment indicators were present and no impairment was recognized.
		2014		2013		2012
	Goodwill impairment	—		—		—
	The changes in the carrying amount of goodwill for the years ended December 31, 2014 and 2013 are as follows (in thousands):
			2014				2013
	Goodwill—beginning balance at January 1		$	357,387			$	240,009
	Goodwill acquired during year		53,462				119,437
	Goodwill adjustment for prior year transactions		(1,861		)		(2,059		)
	Goodwill—ending balance at December 31		$	408,988			$	357,387
Schedule of Other Intangible Assets	At December 31, other intangible assets consist of the following (in thousands):
			2014				2013
	Non-compete agreements		$	2,338			$	2,126
	Hospital and post-acute care facility contracts		10,513				10,088
	Trade name		70				70
			12,921				12,284
	Less: Accumulated amortization		(7,964		)		(6,427		)
			$	4,957			$	5,857
Schedule of Amortization Expenses of Other Intangible Assets	For the years ended December 31, the following amortization of other intangible assets was included in total depreciation and amortization expenses (in thousands):
			2014		2013		2012
	Amortization of other intangible assets		$1,537		$1,304		$943
Schedule of Future Estimated Aggregate Amortization Expenses	Other intangible assets are being amortized over their estimated useful lives which range from three to six years and have a weighted average remaining useful life of 3.5 years at December 31, 2014. Future estimated aggregate amortization expenses are as follows (in thousands):
	2015	$	1,160
	2016	933
	2017	688
	2018	469
	2019	469
	Thereafter	1,238
		$	4,957
Schedule of Total Accrued Medical Malpractice Reserves and Related Insurance Receivables	Total accrued medical malpractice reserves and related insurance receivables at December 31 were as follows (in thousands):
			2014								2013
			Assets			Liabilities					Assets	Liabilities
			Insurance			Claims			IBNR	Total	Insurance	Claims	IBNR	Total
			Receivable			Reserve			Reserve	Liabilities	Receivable	Reserve	Reserve	Liabilities
	Current Portion		$12,564			$12,564			515	13,079	$11,653	$11,653	558	12,211
	Long-term Portion		21,574			21,574			25,665	47,239	20,599	20,599	23,445	44,044
	Total		$34,138			$34,138			26,180	60,318	$32,252	$32,252	24,003	56,255

Business_Acquisitions_Tables

Business Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Schedule of Acquisition of Hospitalist Practices	The following table summarizes the total amounts recorded during the years ended December 31, related to the acquisition of physician practices (in thousands):
		2014			2013
	Acquired assets, net of assumed liabilities—paid and accrued:
	Goodwill—current year transactions	$	53,462		$	119,437
	Other intangible assets	637			5,028
	Fixed assets	—			46
	Total acquired assets—current year	54,099			124,511
	Assumed accrued compensation liabilities	—			(569		)
	Goodwill—adjustment for prior year transactions	(1,861		)	(2,059		)
		52,238			121,883
	Cash paid for acquisitions:
	Current year transactions	(30,250		)	(91,322		)
	Contingent consideration	(17,674		)	(12,601		)
	Other—prior year transactions	—			(204		)
	Total cash paid for acquisitions	(47,924		)	(104,127		)
	Change in accrued contingent consideration	(122		)	(6,075		)
	Net change in payable for practice acquisitions	4,192			11,681
	Payable for practice acquisitions, beginning of period	40,719			29,038
	Payable for practice acquisitions, end of period	$	44,911		$	40,719

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Liabilities Measured at Fair Value on Recurring Basis	The following table presents our liabilities measured at fair value on a recurring basis as of December 31, 2014 and 2013 (in thousands):
	Accrued contingent consideration (included in payable for practice acquisitions)	Quoted Price In			Significant Other			Significant	Total Balance
		Active Markets for			Observable Inputs			Unobservable
		Identical Instruments			(Level 2)			Inputs
		(Level 1)						(Level 3)
	2014	$	—		$	—		$44,911	$44,911
	2013	$	—		$	—		$40,719	$40,719
Rollforward for Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs	The following table presents a reconciliation for our liabilities measured at fair value on a recurring basis using significant unobservable inputs (level 3) for the years ended December 31, 2014 and 2013 (dollars in thousands):
	Accrued contingent consideration	2014			2013
	Beginning balance	$	40,719		$	28,834
	Addition through acquisition transactions	23,849			32,620
	Adjustment for prior year transactions	(1,861		)	(2,059		)
	Change in accrued contingent consideration	(122		)	(6,075		)
	Payments	(17,674		)	(12,601		)
	Ending balance	$	44,911		$	40,719

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Interest Costs and Unused Commitment Fees Related to Debt and Credit Facility	Interest costs and unused commitment fees related to our debt and Credit Facility for the years ended December 31 are comprised of the following (in thousands):
		2014		2013		2012
	Interest expense	$	1,208	$	391	$	153
	Unused commitment fees	120		149		184
	Total interest expense	$	1,328	$	540	$	337

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Current and Deferred Income Tax Provision	The following table represents the current and deferred income tax provision for federal and state income taxes attributable to operations (in thousands):
		2014				2013				2012
	Current:
	Federal	$	17,382			$	18,178			$	15,388
	State	2,031				2,222				2,312
	Total current(1)	19,413				20,400				17,700
	Deferred:
	Federal	3,856				4,322				1,997
	State	1,377				975				31
	Total deferred	5,233				5,297				2,028
	Total provision	$	24,646			$	25,697			$	19,728
	(1)    Current tax provision excludes tax benefit from stock compensation recorded to additional paid-in capital in the amount of:	$	(953	)		$	(2,609	)		$	(988	)
Schedule of Reconciliation of Provision for Income Taxes Compared with U.S. Statutory Tax Rates	A reconciliation of the provision for income taxes compared with U.S. statutory tax rates for the years ended December 31 is shown below:
		2014			2013			2012
	Statutory federal tax provision	35	%		35	%		35	%
	Increase (decrease) in taxes resulting from:
	State tax net of federal benefit	3.48	%		3.1	%		2.91	%
	Change in valuation allowance	(0.16	)%		0.05	%		(0.22	)%
	Permanent differences and other	0.39	%		0.15	%		0.01	%
	Recognition of tax benefits for uncertain positions	—	%		—	%		—	%
	Income tax provision	38.71	%		38.3	%		37.7	%
Schedule of Significant Components of Deferred Tax Assets and Liabilities	At December 31, the significant components of our deferred tax assets and liabilities consisted of the following (in thousands):
		2014				2013
	Deferred tax assets:
	Net operating loss (NOL) carryforwards	$	581			$	575
	Allowance for uncollectible accounts	2,387				2,562
	Compensation accruals	1,779				1,564
	Accrued IBNR claims	10,302				9,445
	Stock-based compensation	8,102				6,611
	State taxes and credits	5,002				3,604
	Other	710				492
	Total deferred tax assets	28,863				24,853
	Less: Valuation allowance	(4,445		)		(2,746		)
	Deferred tax assets, net	24,418				22,107
	Deferred tax liabilities:
	Prepaid insurance	(5,596		)		(5,349		)
	Depreciation and amortization	(31,143		)		(23,489		)
	Total deferred tax liabilities	(36,739		)		(28,838		)
	Total net deferred tax liability	$	(12,321	)		$	(6,731	)

Defined_Contribution_Plan_Tabl

Defined Contribution Plan (Tables)	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Schedule of Expense Recognized in Connection with Employer Contributions	For the years ended December 31, expense recognized in connection with our contributions was (in thousands):
		2014	2013	2012
	Employer contribution to defined contribution plan	$9,941	$8,728	$7,484

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Components of Stock-Based Compensation Expense Recognized in Consolidated Statement of Income	The following table summarizes the components of stock-based compensation expense recognized in our Consolidated Statement of Income for 2014, 2013 and 2012 (in thousands):
		2014				2013				2012
	Total stock-based compensation expense	$	8,282			$	7,355			$	6,344
	Tax benefit from stock-based compensation expense	(3,205		)		(2,817		)		(2,392		)
	Total stock-based compensation expense, net of tax	$	5,077			$	4,538			$	3,952
Schedule of Unrecognized Compensation Costs Related to Non-Vested Stock-Based Compensation Arrangements Granted under Equity Plan and Weighted-Average Period of Years Expected to Recognize Those Costs	As of December 31, 2014, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under our Equity Plan and the weighted-average period of years expected to recognize those costs are as follows (dollars in thousands).
		Total Unrecognized				Weighted-Average
		Compensation Cost				Remaining Contractual
						Term
						(Years)
	Stock option	$	1,687			5.22
	Restricted stock	$	6,603			1.16
Schedule of Fair Value of Each Option Grant Estimated on Date of Grant Using Black-Scholes Option-Pricing Model	The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions:
		For Years Ended December 31,
		2014			2013			2012
	Risk-free interest rate	1.1	%		0.67	%		1.21	%
	Expected volatility	37.11	%		40.07	%		39.86	%
	Expected option life (in years)	4.44			4.4			6.16
	Expected dividend yield	—	%		—	%		—	%
Summary of Stock Option Activity in Equity Plan	The following table summarizes the stock option activity in our Equity Plan during the year ended December 31, 2014.
		Shares			Weighted-				Weighted-		Aggregate		Weighted-
					Average				Average		Intrinsic Value		Average Fair
					Exercise Price				Remaining				Value
									Contractual
									Term
									(Years)		(in 000’s)
	Options outstanding as of December 31, 2013	1,380,425			$	30.12							$	12.56
	Changes during period:
	Granted	44,885			53.74								17.2
	Exercised	(151,008	)		25.87								10.99
	Cancelled	(39,772	)		42.41								17.91
	Expired
	Options outstanding as of December 31, 2014	1,234,530			$	31.1			5.22		$	18,661	$	12.75
	Options exercisable as of December 31, 2014	1,113,763			$	29.92			5.07		$	18,041	$	12.4
Summary of Restricted Stock Award and Performance Stock Award Activities in Equity Plan	The following table summarizes the restricted stock award and performance stock award activities in our Equity Plan during the year ended December 31, 2014.
		Shares			Weighted-		Aggregate				Weighted-
					Average		Intrinsic Value				Average Fair
					Remaining						Value
					Contractual
					Term
					(Years)		(in 000’s)
	Restricted/performance stock awards outstanding as of December 31, 2013	212,413									$	40.29
	Changes during period:
	Granted	119,293									51.94
	Vested	(55,071	)								38.82
	Cancelled/Forfeited	(11,416	)								43.46
	Restricted/performance stock awards outstanding as of December 31, 2014	265,219			1.16		$	12,171			$	45.69

Employee_Stock_Purchase_Plan_T

Employee Stock Purchase Plan (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock-Based Compensation Expense Related to ESPP	For the years ended December 31, the stock-based compensation expense relating to the ESPP was included in general and administrative expenses as follows (in thousands):
		2014	2013	2012
	Stock-based compensation expense related to ESPP	$290	$329	$309

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Income Per Share	The calculations of basic and diluted net income per share for the years ended December 31 are as follows (dollar in thousands, except for per share data):
		2014			2013		2012
	Basic:
	Net income attributable to common stockholders	$	39,020		$	41,396	$	32,586
	Weighted average number of common shares outstanding	17,145,017			16,811,571		16,578,994
	Basic net income per share attributable to common stockholders	$	2.28		$	2.46	$	1.97
	Diluted:
	Net income attributable to common stockholders	$	39,020		$	41,396	$	32,586
	Weighted average number of common shares outstanding	17,145,017			16,811,571		16,578,994
	Weighted average number of dilutive common share equivalents from options to purchase common stock	474,033			503,188		389,151
	Common shares and common share equivalents	17,619,050			17,314,759		16,968,145
	Diluted net income per share	$	2.21		$	2.39	$	1.92
Schedule of Stock Options Excluded from Dilute Shares Computation	Outstanding stock options, which have an exercise price above market or which are anti-dilutive under the treasury stock method, are excluded from our diluted computation. As of December 31, the excluded stock options were as follows:
		2014		2013	2012
	Stock options excluded from diluted shares computation	79,635		28,194	430,489

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments	Future minimum rental payments required under operating leases that have initial or remaining non-cancelable leases as of December 31, 2014, are as follows (in thousands):
	2015	$	4,879
	2016	4,648
	2017	4,145
	2018	3,722
	2019	1,426
	Thereafter	2,319
		$	21,139
Schedule of Rent Expense	We do not have contingent rent and sub-lease agreements. Rent expense recorded for years ended December 31 was as follows (in thousands):
			2014	2013	2012
	Total rent expense		$4,402	$3,595	$3,330

Quarterly_Results_of_Operation1

Quarterly Results of Operations (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Results of Operations	Following is a summary of our quarterly results of operations for the years ended December 31, 2014 and 2013 (dollars in thousands, except for per share data):
			Dec 31,			Sep 30,			Jun 30,			Mar 31,			Dec 31,			Sep 30,			Jun 30,			Mar 31,
			2014			2014			2014			2014			2013			2013			2013			2013
	Net revenue		$	179,234		$	169,757		$	172,268		$	172,726		$	161,600		$	149,073		$	145,753		$	153,091
	Income from operations		16,142			14,307			17,576			16,964			15,658			14,791			20,032			17,139
	Investment income		1			2			1			1			1			7			3			2
	Interest expense		(271		)	(361		)	(382		)	(314		)	(217		)	(109		)	(99		)	(115		)
	Income before income taxes		15,872			13,948			17,195			16,651			15,442			14,689			19,936			17,026
	Income tax provision		6,342			5,341			6,586			6,377			5,915			5,626			7,635			6,521
	Net income		$	9,530		$	8,607		$	10,609		$	10,274		$	9,527		$	9,063		$	12,301		$	10,505
	Per share data:
	Net income per share(1):
	Basic		$	0.55		$	0.5		$	0.62		$	0.6		$	0.56		$	0.54		$	0.73		$	0.63
	Diluted		$	0.54		$	0.49		$	0.61		$	0.58		$	0.54		$	0.52		$	0.71		$	0.61
	Weighted average shares:
	Basic		17,211,617			17,187,819			17,123,840			17,054,598			16,937,646			16,839,069			16,763,325			16,703,369
	Diluted		17,655,522			17,652,892			17,515,938			17,567,583			17,516,086			17,368,426			17,228,173			17,125,940
	-1	Earnings per share are computed independently for each of the quarters presented and therefore may not sum to the total for the year.

Operations_and_Significant_Acc3

Operations and Significant Accounting Policies - Principles of Consolidation (Details)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Initial term period of management agreements	20 years
Renewal term period of agreements	10 years

Operations_and_Significant_Acc4

Operations and Significant Accounting Policies - Revenue (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Concentration Risk [Line Items]
Uncollectible accounts excluded from net revenue	$16,851	$15,274	$14,611
Medicare and Medicaid [Member] | Patients [Member]
Concentration Risk [Line Items]
Concentration risk (as a percentage)	54.00%	53.00%	52.00%

Operations_and_Significant_Acc5

Operations and Significant Accounting Policies - Accounts Receivable and Concentrations of Credit Risk (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Allowance for uncollectible accounts	6,067	6,510
Net Revenue [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk (as a percentage)	57.00%	59.00%	60.00%
Accounts Receivable [Member] | Medicare and Medicaid [Member]
Concentration Risk [Line Items]
Concentration risk (as a percentage)	54.00%	43.00%

Operations_and_Significant_Acc6

Operations and Significant Accounting Policies - Property and Equipment (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$31,800	$25,500
Less: Accumulated depreciation and amortization	-23,002	-19,157
Property and equipment, net total	8,798	6,343
Depreciation and amortization	3,844	3,377	2,968
Furniture [Member]
Property, Plant and Equipment [Line Items]
Depreciable life in years	7 years
Property and equipment, gross	3,057	2,803
Equipment and software [Member]
Property, Plant and Equipment [Line Items]
Depreciable life in years	3 years
Property and equipment, gross	24,154	19,685
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,214	1,925
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$2,375	$1,087

Operations_and_Significant_Acc7

Operations and Significant Accounting Policies - Goodwill (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Goodwill impairment	$0	$0	$0
Goodwill [Roll Forward]
Goodwill-beginning balance	357,387,000	240,009,000
Goodwill acquired during year	53,462,000	119,437,000
Goodwill-adjustment for prior year transactions	-1,861,000	-2,059,000
Goodwill-ending balance	$408,988,000	$357,387,000	$240,009,000

Operations_and_Significant_Acc8

Operations and Significant Accounting Policies - Other Intangible Assets (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Non-compete agreements	$2,338	$2,126
Hospital and post-acute care facility contracts	10,513	10,088
Trade name	70	70
Other intangible assets, gross	12,921	12,284
Less: Accumulated amortization	-7,964	-6,427
Other intangible assets, net	4,957	5,857
Amortization of Intangible Assets	1,537	1,304	943
Finite-Lived Intangible Assets [Line Items]
Other intangible assets estimated useful life	3 years 6 months
Future estimated aggregate amortization expenses
2015	1,160
2016	933
2017	688
2018	469
2019	469
Thereafter	1,238
Other intangible assets, net	$4,957	$5,857
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets estimated useful life	3 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets estimated useful life	6 years

Operations_and_Significant_Acc9

Operations and Significant Accounting Policies - Medical Malpractice Liability Insurance (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Malpractice Insurance [Line Items]
Insurance, Current Portion	$12,564	$11,653
Insurance, Long-term Portion	21,574	20,599
Insurance Receivable, Total	34,138	32,252
Total Liabilities, Current Portion	13,079	12,211
Total Liabilities, Long-term Portion	47,239	44,044
Total Liabilities	60,318	56,255
Claims Reserve
Malpractice Insurance [Line Items]
Total Liabilities, Current Portion	12,564	11,653
Total Liabilities, Long-term Portion	21,574	20,599
Total Liabilities	34,138	32,252
IBNR Reserve
Malpractice Insurance [Line Items]
Total Liabilities, Current Portion	515	558
Total Liabilities, Long-term Portion	25,665	23,445
Total Liabilities	$26,180	$24,003

Business_Acquisitions_Addition

Business Acquisitions - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Dec. 31, 2014	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	practice	practice	practice
Business Acquisition [Line Items]
Number of hospitalist physician practices acquired	7	8	22
Net change in fair value of contingent consideration			($2,252,000)	$5,733,000	($324,000)
Period in which identifiable intangible assets amortized for tax purposes, years			15 years
Increase (decrease) in contingent consideration			-4,192,000	-11,681,000
Adjustment [Member]
Business Acquisition [Line Items]
Increase (decrease) in contingent consideration			($1,861,000)
Business Acquisitions, Providing Contingent Consideration Payments [Member]
Business Acquisition [Line Items]
Number of hospitalist physician practices acquired			21

Business_Acquisitions_Schedule

Business Acquisitions - Schedule of Acquisition of Hospitalist Practices (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Acquired assets, net of assumed liabilities-paid and accrued:
Goodwill-current year transactions	$53,462	$119,437
Other intangible assets	637	5,028
Fixed assets	0	46
Total acquired assets-current year	54,099	124,511
Assumed accrued compensation liabilities	0	-569
Goodwill-adjustment for prior year transactions	-1,861	-2,059
Total acquired assets	52,238	121,883
Cash paid for acquisitions:
Current year transactions	-30,250	-91,322
Contingent consideration	-17,674	-12,601
Other-prior year transactions	0	-204
Total cash paid for acquisitions	-47,924	-104,127
Change in accrued contingent consideration	-122	-6,075	324
Increase in contingent consideration	-4,192	-11,681
Payable for practice acquisitions, beginning of period	40,719	29,038
Payable for practice acquisitions, end of period	$44,911	$40,719	$29,038

Fair_Value_Measurement_Liabili

Fair Value Measurement - Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration (included in payable for practice acquisitions)	$44,911	$40,719
Quoted Price In Active Markets for Identical Instruments (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration (included in payable for practice acquisitions)	0	0
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration (included in payable for practice acquisitions)	0	0
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration (included in payable for practice acquisitions)	$44,911	$40,719

Fair_Value_Measurement_Rollfor

Fair Value Measurement - Rollforward for Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Adjustment for prior year transactions	$1,861	$2,059
Change in accrued contingent consideration	-122	-6,075	324
Payments	-17,674	-12,601
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	40,719	28,834
Addition through acquisition transactions	23,849	32,620
Adjustment for prior year transactions		2,059
Payments	-17,674	-12,601
Ending balance	$44,911	$40,719

Fair_Value_Measurement_Additio

Fair Value Measurement - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014
Minimum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Discount rate on significant inputs	1.33%
Probability of earnings or other achievements	10.00%
Maximum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Discount rate on significant inputs	2.40%
Probability of earnings or other achievements	100.00%

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Oct. 23, 2013
Line of Credit Facility [Line Items]
Revolving line of credit borrowing capacity		$125
Additional borrowing capacity under revolving line of credit facility		25
Amount provided by credit agreement	80
Letters of credit amount outstanding	0.3
Remaining amount available under revolving line of credit facility	$44.70
Percentage of unused commitment fee, per annum	0.25%
LIBOR [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate	0.75%
LIBOR [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate	1.75%
Lender's prime rate [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate	0.00%
Lender's prime rate [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate	0.75%

Debt_Schedule_of_Interest_Cost

Debt - Schedule of Interest Costs and Unused Commitment Fees Related to Debt and Credit Facility (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Debt Disclosure [Abstract]
Interest expense									$1,208	$391	$153
Unused commitment fees									120	149	184
Total interest expense	$271	$361	$382	$314	$217	$109	$99	$115	$1,328	$540	$337

Income_Taxes_Schedule_of_Curre

Income Taxes - Schedule of Current and Deferred Income Tax Provision (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current:
Federal									$17,382	$18,178	$15,388
State									2,031	2,222	2,312
Total current									19,413	20,400	17,700
Deferred:
Federal									3,856	4,322	1,997
State									1,377	975	31
Total deferred									5,233	5,297	2,028
Total provision	6,342	5,341	6,586	6,377	5,915	5,626	7,635	6,521	24,646	25,697	19,728
Current tax provision excludes tax benefit from stock compensation recorded to additional paid-in capital in the amount of									($953)	($2,609)	($988)

Income_Taxes_Schedule_of_Recon

Income Taxes - Schedule of Reconciliation of Provision for Income Taxes Compared with U.S. Statutory Tax Rates (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Statutory federal tax provision	35.00%	35.00%	35.00%
State tax net of federal benefit	3.48%	3.10%	2.91%
Change in valuation allowance	-0.16%	0.05%	-0.22%
Permanent differences and other	0.39%	0.15%	0.01%
Recognition of tax benefits for uncertain positions	0.00%	0.00%	0.00%
Recognition of tax benefits for uncertain positions	38.71%	38.30%	37.70%

Income_Taxes_Schedule_of_Signi

Income Taxes - Schedule of Significant Components of Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Net operating loss (NOL) carryforwards	$581	$575
Allowance for uncollectible accounts	2,387	2,562
Compensation accruals	1,779	1,564
Accrued IBNR claims	10,302	9,445
Stock-based compensation	8,102	6,611
State taxes and credits	5,002	3,604
Other	710	492
Total deferred tax assets	28,863	24,853
Less: Valuation allowance	-4,445	-2,746
Deferred tax assets, net	24,418	22,107
Deferred tax liabilities:
Prepaid insurance	-5,596	-5,349
Depreciation and amortization	-31,143	-23,489
Total deferred tax liabilities	-36,739	-28,838
Total net deferred tax liability	($12,321)	($6,731)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$1,451
Federal [Member] | Tax Year 2000 [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	390
Operating loss carryforwards, annual change of ownership limitation	195
State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	1,663
State [Member] | California [Member]
Operating Loss Carryforwards [Line Items]
Credit carry forwards partial valuation allowance	4,199
Tax credit carryforwards	4,307
General Business Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Credit carry forwards partial valuation allowance	$4,199

Defined_Contribution_Plan_Addi

Defined Contribution Plan - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Percentage of employee's pay, matched against	50.00%
Maximum percentage of participant's annual compensation eligible for employer matching	7.00%
Employer contribution, vesting period, in years	1 year
Number of days to opt out of defined contribution plan to receive refund of contributions	60 days

Defined_Contribution_Plan_Sche

Defined Contribution Plan - Schedule of Expense Recognized in Connection with Employer Contributions (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Compensation and Retirement Disclosure [Abstract]
Employer contribution to defined contribution plan	$9,941	$8,728	$7,484

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Jun. 07, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares reserved for issuance under stock-based employee compensation program	4,943,170
Common stock available for issuance under Equity Plan	915,145	1,422,130
Total intrinsic value of stock option exercised	$2,999
Stock option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, in years	4 years
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, in years	4 years
Performance stock awards [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, in years	2 years
Performance stock awards [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, in years	3 years

StockBased_Compensation_Compon

Stock-Based Compensation - Components of Stock-Based Compensation Expense Recognized in Consolidated Statement of Income (Detail) (General and administrative expenses [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
General and administrative expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$8,282	$7,355	$6,344
Tax benefit from stock-based compensation expense	-3,205	-2,817	-2,392
Total stock-based compensation expense, net of tax	$5,077	$4,538	$3,952

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Unrecognized Compensation Costs under Equity Plan and Weighted-Average Period of Years Expected to Recognize Those Costs (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Stock option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Unrecognized Compensation Cost	$1,687
Weighted-Average Remaining Contractual Term	5 years 2 months 20 days
Restricted stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Unrecognized Compensation Cost	$6,603
Weighted-Average Remaining Contractual Term	1 year 1 month 27 days

StockBased_Compensation_Schedu1

Stock-Based Compensation - Schedule of Fair Value of Each Option Grant Estimated on Date of Grant Using Black-Scholes Option-Pricing Model (Detail) (Stock option [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.10%	0.67%	1.21%
Expected volatility	37.11%	40.07%	39.86%
Expected option life	4 years 5 months 7 days	4 years 4 months 24 days	6 years 1 month 28 days
Expected dividend yield	0.00%	0.00%	0.00%

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of Stock Option Activity in Equity Plan (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014
Shares
Shares, Options outstanding	1,380,425
Shares, Granted	44,885
Shares, Exercised	-151,008
Shares, Cancelled	-39,772
Shares, Expired
Shares, Options outstanding	1,234,530
Shares, Options exercisable	1,113,763
Weighted- Average Exercise Price
Weighted-Average Exercise Price, Options outstanding	$30.12
Weighted-Average Exercise Price, Granted	$53.74
Weighted-Average Exercise Price, Exercised	$25.87
Weighted-Average Exercise Price, Cancelled	$42.41
Weighted-Average Exercise Price, Expired
Weighted-Average Exercise Price, Options outstanding	$31.10
Weighted-Average Exercise Price, Options exercisable	$29.92
Weighted-Average Remaining Contractual Term, Options outstanding (Years)	5 years 2 months 20 days
Weighted-Average Remaining Contractual Term, Options exercisable (Years)	5 years 0 months 25 days
Aggregate Intrinsic Value, Options outstanding	$18,661
Aggregate Intrinsic Value, Options exercisable	$18,041
Weighted- Average Fair Value
Weighted-Average Fair Value, Options outstanding	$12.56
Weighted-Average Fair Value, Granted	$17.20
Weighted-Average Fair Value, Exercised	$10.99
Weighted-Average Fair Value, Cancelled	$17.91
Weighted-Average Fair Value, Expired
Weighted-Average Fair Value, Options outstanding	$12.75
Weighted-Average Fair Value, Options exercisable	$12.40

StockBased_Compensation_Summar1

Stock-Based Compensation - Summary of Restricted Stock Award and Performance Stock Award Activities in Equity Plan (Detail) (Restricted Stock and Performance Shares [Member], USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014
Restricted Stock and Performance Shares [Member]
Shares
Restricted/performance stock awards outstanding	212,413
Shares, Granted	119,293
Shares, Vested	-55,071
Shares, Cancelled/Forfeited	-11,416
Restricted/performance stock awards outstanding	265,219
Weighted-Average Remaining Contractual Term, Restricted/performance stock awards outstanding as of December 31, 2013 (Years)	1 year 1 month 27 days
Aggregate Intrinsic Value, Restricted/performance stock awards outstanding as of December 31, 2013	$12,171
Weighted-Average Fair Value
Weighted-Average Fair Value, Restricted/performance stock awards outstanding	$40.29
Weighted-Average Fair Value, Granted	$51.94
Weighted-Average Fair Value, Vested	$38.82
Weighted-Average Fair Value, Cancelled/Forfeited	$43.46
Weighted-Average Fair Value, Restricted/performance stock awards outstanding	$45.69

Employee_Stock_Purchase_Plan_D

Employee Stock Purchase Plan (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized for issuance to eligible employees	4,943,170
Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized for issuance to eligible employees	306,250
Stock purchase price as a percentage of fair market value	85.00%
Stock-based compensation expense related to ESPP	$290,000	$329,000	$309,000
Employee Stock [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase of common stock as through payroll deductions, per year	500
Employee Stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase of common stock as through payroll deductions, per year	$10,000

Earnings_Per_Share_Schedule_of

Earnings Per Share - Schedule of Basic and Diluted Net Income Per Share (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Basic:
Net income attributable to common stockholders									$39,020	$41,396	$32,586
Weighted average number of common shares outstanding	17,211,617	17,187,819	17,123,840	17,054,598	16,937,646	16,839,069	16,763,325	16,703,369	17,145,017	16,811,571	16,578,994
Basic net income per share attributable to common stockholders	$0.55	$0.50	$0.62	$0.60	$0.56	$0.54	$0.73	$0.63	$2.28	$2.46	$1.97
Diluted:
Net income attributable to common stockholders									$39,020	$41,396	$32,586
Weighted average number of common shares outstanding	17,211,617	17,187,819	17,123,840	17,054,598	16,937,646	16,839,069	16,763,325	16,703,369	17,145,017	16,811,571	16,578,994
Weighted average number of dilutive common share equivalents from options to purchase common stock									474,033	503,188	389,151
Common shares and common share equivalents	17,655,522	17,652,892	17,515,938	17,567,583	17,516,086	17,368,426	17,228,173	17,125,940	17,619,050	17,314,759	16,968,145
Diluted net income per share	$0.54	$0.49	$0.61	$0.58	$0.54	$0.52	$0.71	$0.61	$2.21	$2.39	$1.92

Earnings_Per_Share_Schedule_of1

Earnings Per Share - Schedule of Stock Options Which Have Exercise Price Above Market or Which are Anti-Dilutive under Treasury Stock Method (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]
Stock options excluded from diluted shares computation	79,635	28,194	430,489

Commitments_and_Contingencies_1

Commitments and Contingencies (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Commitments and Contingencies Disclosure [Abstract]
2015	$4,879
2016	4,648
2017	4,145
2018	3,722
2019	1,426
Thereafter	2,319
Future minimum rental payments, Total	21,139
Total rent expense	$4,402	$3,595	$3,330

Quarterly_Results_of_Operation2

Quarterly Results of Operations (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Net revenue	$179,234	$169,757	$172,268	$172,726	$161,600	$149,073	$145,753	$153,091
Income from operations	16,142	14,307	17,576	16,964	15,658	14,791	20,032	17,139	64,989	67,620	52,637
Investment income	1	2	1	1	1	7	3	2	5	13	14
Interest expense	-271	-361	-382	-314	-217	-109	-99	-115	-1,328	-540	-337
Income before income taxes	15,872	13,948	17,195	16,651	15,442	14,689	19,936	17,026	63,666	67,093	52,314
Income tax provision	6,342	5,341	6,586	6,377	5,915	5,626	7,635	6,521	24,646	25,697	19,728
Net income	$9,530	$8,607	$10,609	$10,274	$9,527	$9,063	$12,301	$10,505	$39,020	$41,396	$32,586
Net income per share:
Net income per share, Basic	$0.55	$0.50	$0.62	$0.60	$0.56	$0.54	$0.73	$0.63	$2.28	$2.46	$1.97
Net income per share, Diluted	$0.54	$0.49	$0.61	$0.58	$0.54	$0.52	$0.71	$0.61	$2.21	$2.39	$1.92
Weighted average shares:
Weighted average shares: Basic	17,211,617	17,187,819	17,123,840	17,054,598	16,937,646	16,839,069	16,763,325	16,703,369	17,145,017	16,811,571	16,578,994
Weighted average shares: Diluted	17,655,522	17,652,892	17,515,938	17,567,583	17,516,086	17,368,426	17,228,173	17,125,940	17,619,050	17,314,759	16,968,145

Subsequent_Events_Detail

Subsequent Events (Detail)	3 Months Ended		12 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2012	Dec. 31, 2014	Jan. 02, 2015
	practice	practice	practice	Hospitalist
Subsequent Event [Line Items]
Number of hospitalist physician practices acquired	7	8	22
Subsequent Events [Member]
Subsequent Event [Line Items]
Number of hospitalist physician practices acquired				4

Schedule_II_Valuation_and_Qual1

Schedule II: Valuation and Qualifying Accounts (Detail) (Allowance for Uncollectible Accounts, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for Uncollectible Accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of year	$6,510	$4,837	$4,831
Amount charged against operating revenue	16,851	15,274	14,611
Accounts receivable write-offs (net of recovery)	-17,294	-13,601	-14,605
Balance at end of year	$6,067	$6,510	$4,837